The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn’s disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

白介素（IL）-23 / IL-17轴在免疫介导的疾病（如牛皮癣，牛皮癣关节炎，克罗恩病和葡萄膜炎）的发病机理中起着重要作用。因此，靶向IL-23 / IL-17轴已成为针对自身免疫性疾病患者进行药物开发的多项临床试验的重点。我们简要描述了IL-23 / IL-17轴的生物学特性及其与实验和临床葡萄膜炎发病机制的相关性，并综述了针对该途径的单克隆抗体疗法。最后，针对抗感染性葡萄膜炎的患者，进行了两项正在进行的抗IL-23生物疗法ustekinumab（STELARA，Janssen Biotech Inc，宾夕法尼亚州霍舍姆）的2期临床试验。